Literature DB >> 33062178

Mechanism-Based Design of 3-Amino-4-Halocyclopentenecarboxylic Acids as Inactivators of GABA Aminotransferase.

Sida Shen1, Peter F Doubleday1, Pathum M Weerawarna1, Wei Zhu1, Neil L Kelleher1,1, Richard B Silverman1,1,2.   

Abstract

Aminotransferases are pyridoxal 5'-phosphate-dependent enzymes that catalyze reversible transamination reactions between an amino acid and an α-keto acid, playing a critical role in cellular nitrogen metabolism. It is evident that γ-aminobutyric acid aminotransferase (GABA-AT), which balances the levels of inhibitory and excitatory neurotransmitters, has emerged as a promising therapeutic target for epilepsy and cocaine addiction based on mechanism-based inactivators (MBIs). In this work, we established an integrated approach using computational simulation, organic synthesis, biochemical evaluation, and mass spectrometry to facilitate our design and mechanistic studies of MBIs, which led to the identification of a new cyclopentene-based analogue (6a), 25-times more efficient as an inactivator of GABA-AT compared to the parent compound (1R,3S,4S)-3-amino-4-fluorocyclopentane carboxylic acid (FCP, 4).

Entities:  

Year:  2020        PMID: 33062178      PMCID: PMC7549257          DOI: 10.1021/acsmedchemlett.9b00672

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

Review 1.  The potential use of mechanism-based enzyme inactivators in medicine.

Authors:  R B Silverman
Journal:  J Enzyme Inhib       Date:  1988

2.  Skeletal rearrangements in the 2,3-diazanorbornene series. A fast access to highly functionalized cyclopentanes.

Authors:  Chloée Bournaud; Martine Bonin; Laurent Micouin
Journal:  Org Lett       Date:  2006-07-06       Impact factor: 6.005

3.  Selective Targeting by a Mechanism-Based Inactivator against Pyridoxal 5'-Phosphate-Dependent Enzymes: Mechanisms of Inactivation and Alternative Turnover.

Authors:  Romila Mascarenhas; Hoang V Le; Kenneth D Clevenger; Helaina J Lehrer; Dagmar Ringe; Neil L Kelleher; Richard B Silverman; Dali Liu
Journal:  Biochemistry       Date:  2017-09-06       Impact factor: 3.162

4.  Two continuous coupled assays for ornithine-δ-aminotransferase.

Authors:  Jose I Juncosa; Hyunbeom Lee; Richard B Silverman
Journal:  Anal Biochem       Date:  2013-06-05       Impact factor: 3.365

Review 5.  Design and Mechanism of GABA Aminotransferase Inactivators. Treatments for Epilepsies and Addictions.

Authors:  Richard B Silverman
Journal:  Chem Rev       Date:  2018-03-23       Impact factor: 60.622

6.  A new class of conformationally rigid analogues of 4-amino-5-halopentanoic acids, potent inactivators of gamma-aminobutyric acid aminotransferase.

Authors:  J Qiu; R B Silverman
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

7.  Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.

Authors:  John M Wild; Philip E M Smith; Carlo Knupp
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

8.  Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.

Authors:  Gregory Krauss; Edward Faught; Rod Foroozan; John M Pellock; Robert C Sergott; W Donald Shields; Adam Ziemann; Yekaterina Dribinsky; Deborah Lee; Sarah Torri; Feisal Othman; Jouko Isojarvi
Journal:  Epilepsy Behav       Date:  2016-01-22       Impact factor: 2.937

9.  Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction.

Authors:  Jose I Juncosa; Kenji Takaya; Hoang V Le; Matthew J Moschitto; Pathum M Weerawarna; Romila Mascarenhas; Dali Liu; Stephen L Dewey; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2018-01-30       Impact factor: 15.419

10.  A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms.

Authors:  Kyra Doumlele; Erin Conway; Julie Hedlund; Patricia Tolete; Orrin Devinsky
Journal:  Epilepsy Behav Case Rep       Date:  2016-08-21
View more
  3 in total

1.  Rational Design, Synthesis, and Mechanism of (3S,4R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase.

Authors:  Wei Zhu; Arseniy Butrin; Rafael D Melani; Peter F Doubleday; Glaucio Monteiro Ferreira; Mauricio T Tavares; Thahani S Habeeb Mohammad; Brett A Beaupre; Neil L Kelleher; Graham R Moran; Dali Liu; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2022-03-16       Impact factor: 16.383

2.  Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase.

Authors:  Wei Zhu; Peter F Doubleday; Arseniy Butrin; Pathum M Weerawarna; Rafael D Melani; Daniel S Catlin; Timothy A Dwight; Dali Liu; Neil L Kelleher; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2021-05-20       Impact factor: 16.383

3.  Turnover and Inactivation Mechanisms for (S)-3-Amino-4,4-difluorocyclopent-1-enecarboxylic Acid, a Selective Mechanism-Based Inactivator of Human Ornithine Aminotransferase.

Authors:  Sida Shen; Arseniy Butrin; Peter F Doubleday; Rafael D Melani; Brett A Beaupre; Mauricio T Tavares; Glaucio M Ferreira; Neil L Kelleher; Graham R Moran; Dali Liu; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2021-06-07       Impact factor: 16.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.